Shots:
- Aqemia has expanded its multi-year research collaboration with Sanofi, marked by the nomination of a new therapeutic target & an additional payment
- The collaboration, initially announced in Dec 2023, makes Aqemia eligible to receive up to a total of $140M in upfront & milestone payments across programs
- Aqemia uses its physics-based generative AI platform, Qemi, to design novel small molecules against Sanofi-selected targets, while Sanofi leads laboratory research, development, & commercialization
Ref: Businesswire | Image: Aqemia & Sanofi | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
